SecBot SecBot
SECBOTREPLAY Home › Report › VVOS

VVOS · Vivos Therapeutics filed additional definitive proxy soliciting…

Vivos Therapeutics, Inc. · DEFA14A filed Nov 2, 2026 at 06:02 ET

At the news

BEARISHIMPACT 6/10

DEFA14A filed Nov 2, 2026 at 06:02 ET

Vivos Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) on November 2, 2026, four days after its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting. The filing does not contain new substantive text beyond the cover page and graphic images; the proxy statement itself seeks shareholder approval on 10 proposals including a reverse stock split, massive potential share issuances to two investors, an equity plan increase, and a reincorporation from Delaware to Nevada. The company has a $4M market cap, widening net losses ($21.2M in 2025 vs $11.1M in 2024), and substantial dilution risk from existing convertible securities.

  • DEFA14A filed on 2026-11-02, supplementing the DEF 14A filed 2026-10-29 for the 2026 Annual Meeting
  • 10 proposals include reverse stock split (1-for-20 to 1-for-40), potential issuance of up to 18.5M shares to New Seneca Partners and up to 80M shares to SOD Sciences, 4.9M share increase to equity plan, and reincorporation from Delaware to Nevada
  • Market cap is $4M; net loss widened to $21.2M in 2025 from $11.1M in 2024
  • CEO compensation actually paid was negative per the proxy statement

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access